Short Interest Reporting: What’s Ahead for Voyager Therapeutics Incorporated (NASDAQ:VYGR) After More Shorted Shares?

November 21, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Reporting: What’s Ahead for Voyager Therapeutics Incorporated (NASDAQ:VYGR) After More Shorted Shares?

The stock of Voyager Therapeutics Incorporated (NASDAQ:VYGR) registered an increase of 2.24% in short interest. VYGR’s total short interest was 775,000 shares in November as published by FINRA. Its up 2.24% from 758,000 shares, reported previously. With 59,200 shares average volume, it will take short sellers 13 days to cover their VYGR’s short positions. The short interest to Voyager Therapeutics Incorporated’s float is 7.43%. The stock closed at $13.99 during the last session. It is down 12.19% since April 19, 2016 and is uptrending. It has outperformed by 8.33% the S&P500.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The company has a market cap of $355.52 million. The Firm is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system . It currently has negative earnings. The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Voyager Therapeutics Inc (NASDAQ:VYGR) Ratings Coverage

Out of 6 analysts covering Voyager Therapeutics (NASDAQ:VYGR), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Voyager Therapeutics has been the topic of 7 analyst reports since December 7, 2015 according to StockzIntelligence Inc. The stock of Voyager Therapeutics Inc (NASDAQ:VYGR) earned “Outperform” rating by Cowen & Co on Monday, December 7. Stifel Nicolaus initiated Voyager Therapeutics Inc (NASDAQ:VYGR) rating on Friday, July 15. Stifel Nicolaus has “Buy” rating and $33 price target. Piper Jaffray initiated Voyager Therapeutics Inc (NASDAQ:VYGR) on Monday, December 7 with “Overweight” rating. Wells Fargo initiated Voyager Therapeutics Inc (NASDAQ:VYGR) on Friday, May 20 with “Outperform” rating. The stock of Voyager Therapeutics Inc (NASDAQ:VYGR) has “Neutral” rating given on Monday, January 25 by Chardan Capital Markets. The firm has “Sell” rating given on Wednesday, December 9 by Chardan Capital Markets. The company was initiated on Monday, December 7 by Wedbush.

VYGR Company Profile

Voyager Therapeutics, Inc., incorporated on June 19, 2013, is a clinical-stage gene therapy company. The Firm is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Depending on the disease, its gene therapies uses either gene replacement or gene knockdown techniques.

More news for Voyager Therapeutics Inc (NASDAQ:VYGR) were recently published by: Nasdaq.com, which released: “The News From Voyager Therapeutics (VYGR) May Be More Significant Than Many Think” on September 14, 2016. Businesswire.com‘s article titled: “Voyager Therapeutics Appoints Michael Higgins to Board of Directors” and published on July 22, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>